POINT Biopharma Global Inc. (NASDAQ: PNT), a company aimed at accelerating the discovery, development, and global access to life changing radiopharmaceuticals, recently announced the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of its Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

The open-label safety and dosimetry lead-in enrolled patients with PSMA-expressing mCRPC have progressed on ARAT therapy and are ineligible or averse to chemotherapy. Data generated from the initial safety lead-in phase of the study will be analyzed before proceeding to the randomization phase, with site initiation in the United Kingdom and several European Union countries beginning shortly thereafter. Patient treatment and follow-ups remain ongoing, and the company expects to report data from this phase of the study at a future scientific conference.

To read more please visit:

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC-POINT Biopharma

Source: POINT Biopharma